Why did CHM.AX stock drop 20.0% today?

CHM.AX stock fell largely due to thin liquidity amplifying negative sentiment tied to trial and funding risk. The small market cap **A$8,837,400** and wide bid‑ask at **A$0.002** magnified selling pressure.

What is Meyka AI's view on CHM.AX stock?

Meyka AI rates CHM.AX **62.23/100 (B, HOLD)**. The model highlights trial risk, tight liquidity and a potential upside target of **A$0.0100**, but stresses forecasts are not guarantees.

What financial metrics should investors watch for CHM.AX stock?

Key metrics are cash per share **A$0.0034**, current ratio **0.72**, EPS **-0.01**, and any capital raises. These show short‑term funding risk for CHM.AX stock.

Is CHM.AX stock a buy after the intraday drop?

CHM.AX stock remains high risk. A deeper dip can offer an entry only if you accept clinical binary risk and possible dilution. We advise monitoring trial milestones and funding announcements.

AU Stocks

CHM.AX stock down 20.0% intraday on ASX: catalysts point to funding and trial risks

ByHuzaifa Zahoor January 17, 2026January 17, 2026

CHM.AX stock plunged 20.0% intraday to A$0.002 on 17 Jan 2026 on the ASX, making it one of today’s top losers. Trading volume is 1,013,423 shares versus a 50‑day average of 8,062,349 shares, suggesting focused selling. We see the move as a reaction to thin liquidity, clinical trial execution risk and funding concerns for this biotechnology developer. Below we break down the drivers, the balance sheet, technical signals and a short-term price forecast to help investors weigh risk and opportunity.